Usana Health Sciences Lowers FY2026 Adj EPS Guidance from $1.95-$2.29 to $0.76 vs $2.12 Est; Lowers FY2026 Sales Guidance from $925.000M-$1.000B to $910.000M vs $945.097M Est

Usana Health Sciences (NYSE:USNA) lowers FY2026 Adj EPS guidance from $1.95-$2.29 to $0.76 vs $2.12 analyst estimate. Lowers FY2026 sales outlook from $925.000 million-$1.000 billion to $910.000 million vs $945.097 million estimate.